In an attempt to investigate the incidence and clinical course of type C viral hepatitis among patients with posttransfusion hepatitis, antibodies to hepatitis C virus (anti-HCV) in sera were measured from 42 prospectivelyfollowed cardiovascular surgery patients who developedhepatitis after blood transfusions. Of these, 35 (83.3%) had anti-HCV seroconversion during a 6-to 12-month follow-up period. The mean interval between blood transfusion and onset of active anti-HCV seroconversion was "'3 months after the first elevationof serum alanine aminotransferase levels (18.1 vs,6.4weeks). There was no correlation betweenfluctuations in serum alanine aminotransferase levelsand anti-HCV titers. Of26 patients with type C posttransfusion hepatitis who werefollowed >1 year, 20 (769%) continued to haveabnormal serum alanine aminotransferase levels. The results indicate that HCV is the major agent of posttransfusion hepatitis in Taiwan. Furthermore, it plays an important role in chronic hepatitis among transfused patients.
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Non-A, non-B (NANB) hepatitis is a recognized disease caused by hepatotrophic agents that are not serologically related to either hepatitis A virus or hepatitis B virus. Despite the use of hepatitis B surface antigen in screeningof all blood donors after the 1970s, transfusion-associated hepatitis stilloccursoccasionally in bloodrecipients, andthe NANB virus mayplaya major role [1] [2] [3] [4] . According to somereports [2, [4] [5] [6] [7] [8] , the incidence of NANB hepatitis after transfusion ranges from 6% to 17% in differentcountries. Thus NANB hepatitisremainsthe most commonserious eventafter blood transfusion.
Toreducethe incidenceof transfusion-related NANBhepatitis, a specificserologictest for the NANBvirus is urgently needed. Unfortunately, all attempts to develop sucha test have been unsuccessful, althougha specificblood test for the hepatitis C virus (HCV) was developed recently using recombinant DNA technology [9, 10] . This test showed that 80% of chronicNANB posttransfusion hepatitisin patientsin Italy andJapanand58%in patients in the United Stateswerecaused by HCV [10] .
In an attemptto investigate theincidence andclinicalcourse of NANB hepatitis after blood transfusions in Taiwan, we prospectively studied NANB hepatitis after transfusions in Taipei from 1981 to 1989 [4] . In that study, 13% of patients who had cardiovascular surgery and blood transfusions de-veloped posttransfusion hepatitis, and 92% of such patients had NANBhepatitis. Weused an ELISAto detect antibodies to HCV (anti-HCV), using stored serum samples from the prospective study of posttransfusion hepatitis [4] , to determine the frequency with which HCV was responsible. The clinical course of HCV-related posttransfusionhepatitis and its correlation withanti-HCV persistence werealso evaluated.
Materials and Methods
A prospective studyof NANBhepatitis amongpatientswho had cardiovascular surgeryand blood transfusions at Veterans General Hospitalin Taipei between 1981 and 1989 revealed 42 patientswith posttransfusion hepatitis [4] . All were followed for serum liver aminotransferase levels periodically for >6 months. During the study, serumsamples wereobtained before and3 days afterthebloodtransfusion. Further serum samples were collected weekly in the first month, biweekly in the next2 months, and monthly thereafteruntil 1 year. When hepatitis was diagnosed, the patient was placed on long-term clinical follow-up; theinterval between samplings depended on the clinical course of disease.
Hepatitis was diagnosed when, from 2 weeks to 6 months after transfusion, twoconsecutive serumalanine aminotransferase (ALT) levels exceeded twotimestheuppernormalvalue (>90 lUll) in samples drawn at intervals >2 weeks. NANB hepatitis was diagnosed if there was no serologic evidence of acute hepatitis A or B, cytomegalovirus (CMV), or Epstein-Barr virus (EBV) infection. Other likely causesof hepatitis (drugs or heartfailure) werealsoexcluded. Chronichepatitis was defined as serum ALT levels remaining high 1 year after transfusion.
Serumsamples frompatients werestoredat -70°C untiltheywere assayed for anti-HCV. Data on serum ALT levels and other viral hepatitis markers for each patientwere obtained from the original study [4] . Serumanti-HCV (HCV antibody ELISA test system; Ortho Diagnostics, Raritan, NJ) was measured by ELISA with a microplate technique done following manufacturer's instructions. Briefly, 20 p.l ofserumwas added withspecimen diluent to theClOO-3 recombinant antigen [9] -coated microwell plate and incubated for 60 min at 37°C. After the plate waswashed,200 ILl of murine monoclonalanti-IgG conjugated to horseradish peroxidase wasadded, and the platewasincubated for 60 min at 37°C.The microplate wasagain washed, 200 ILl of o-phenylenediamine-Z HCI substrate was added to each well, and the plate was incubated at room temperature for 30 min. Fifty microliters of 4 N sulfuric acid was added to each well, and the plate was read at 490 om using a microplate reader. Specimens with absorbancevaluesgreater thanthe cutoffvaluewere considered reactive. Anti-HCV seroconversionwas definedas antibody reactivein two or more sequentialsera or repeatedly reactive. relatively highcomparedwith thoseof cases 1 and 3. Among thesefour, threewerefollowed and had abnormal serumALT levels >1 year, and serum anti-HCV persisted~6-8 years ( figure 1, case 3 ). Passiveanti-HCV was not detectedin sera in mostpatients (82.9%) (figure 2). All patients had a typical delayed active anti-HCV response that usually began8-40 weeks aftertransfusion. Mostpatients had persistentanti-HCV throughout the follow-up period, and chronic hepatitis usually developed (figure2, case 6). Of patientsfollowed >1 year,eight had serum anti-HCV undetectable at 8-21 monthsaftertransfusion.
Results
Of 42 cardiovascular surgery patientswho developed hepatitis after blood transfusions, 39 (92.8%) were considered to have NANB hepatitis, 2 (4.8%) had CMV hepatitis, and 1 (2.4%) wasinfected by EBV. Anti-HCV seroconversion was documented in 35 patients(83.3 %)during6 monthsto 1year of follow-up, including 2 withCMV infection and 1 withEBV infection.
The mean age of the 35 patients with type C hepatitis was 50.3 years(range, 18-73); 71.4%weremen. Afterbloodtransfusion, the onset of active anti-HCVseroconversion (mean, 18.1 weeks; range, 8-40) occurred N12 weeks after the first elevation of serumALT (mean, 6.4weeks; range, 2-16). Most patients (83%) had elevated serum ALT 4-12 weeks after transfusion; 76% had onset of active anti-HCV seroconversion 13-28 weeks later.
Of the 35 patientswith type C hepatitis, 19 (54.3%) were asymptomatic, and only 7 (20%) had total serum bilirubin levels>2 mg/dl; the highest was6.7. Peak serum ALT levels >1000 lUll were noted in 11 patients (31.4%), and only 2 (5.7 %)had levels<300 lUll. There wasno case of fulminant hepatic failure. Of the 35 patients,26 werefollowed >1 year. After 1 year, serum ALT levels remained abnormal in 20 (76.9%) but had returned to normal in6 (23.1%). Three (50%) of the latter lost detectable anti-HCV during the follow-up period (mean, 2.5 years; greatest, 6), while 4 (20%) of the former lost their antibodies (mean follow-up, 3.6 years; greatest, 9).
Representative patterns of the serum anti-HCV response in patientswith type C posttransfusion hepatitis and correlations with serum ALT levels are shown in figures 1 and 2. Passive transfer ofanti-HCV wasnotedin sixpatients (17.1 %). In two patients, active anti-HCV wasnotdetected in thefollowup serum samples and their passive antibodies disappeared at weeks 1 and 3.In both, the levels of passive anti-HCV were low(peak absorbance value ofanti-HCV, 0.557 and0.676 OD). Their serum ALT levels returned to normal within 1 year (figure1, case 1). Another four patientshad activeanti-HCV responses after their passive antibodies disappeared ( figure  1,case 3) . Levels oftheir passive antibodies (peak absorbance value of anti-HCV, 2.745, 1.638, 0.848, and 0.618 OD) were JIO 1991;163 (June) Of these,all exceptone had abnormalserum ALTlevelsafter 1 year (figure2, cases 19,21). No correlation was found betweenthe fluctuations in serum ALTlevelsand thosein anti-HCV titers. In three patients anti-HCVreappearedin serum at low levels at months 21, 24, and 38 (figure 2, case 24). None had received blood transfusion during the follow-up period.
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Discussion
NANB is the mostcommon type oftransfusion-related hepatitis in the world [1] [2] [3] [4] . Since the development of a specific antibody test for HCV [9] , we studiedthe incidenceof HCV infections in prospectively followed patients who developed the disease after blood transfusions.
Consistent with reports from Western countries [10] [11] [12] [13] , HCVappears to be a major cause of NANBposttransfusion hepatitis in Thiwan. In our study, seroconversion to anti-HCV was foundnot only in patientswith NANBhepatitisbut also in transfused patients with CMV or EBV infection. In about half of our patients with type C hepatitis, symptoms were not clinically apparent despite fluctuating serum ALT levels. Only 20% had jaundice at the acute stage. Althoughthe clinicalsymptoms of patientswith acute HCVinfection wererelatively mild, theprogression to chronicity was high: 77% had biochemical evidence of evolution toward chronic hepatitis. This is similar to reports from the United States [11] and Spain [13] .
During this study, we observed that once developed, serum anti-HCV maypersist~9 years. However, antibodies in some patients disappear temporally after a variable period, particularlyin thosein whomserumanti-HCV waslow. This was likely due to the insensitivity of the present anti-HCV assay. Furthermore, sequential serumsamples fromprospectively followed patients withtypeC hepatitis showed thatanti-HCV seroconversion usually was delayed until 8-40 weeks after transfusion. The undetectable levels of anti-HCV and lateanti-HCV seroconversion suggest thatsomedonors capable of transmitting HCV hepatitis cannot be detected by the present assay.
The passive transfer of anti-HCV wasobserved in 17% of our prospectively followed patients withtypeC hepatitis. Two (5.7%) had no active anti-HCV response after passive anti-HCV disappeared, probably because HCV is a poor immunogen, the patient's immune response to the antigen was low, or the presentassay lacks sufficient sensitivity. This suggests that someanti-HCV negative hepatitis is due to HCV. Thus, the incidence of HCV infections among patients with NANB hepatitis may be underestimated at present.
In a studyby Alter et al. [11] , all 3 acutetype C posttransfusion hepatitis patients whose serum ALT returned to normallostdetectable anti-HCV during follow-up compared with 1(6.7 %) of 15whose ALT levels remained elevated. Thisstudy suggested that the disappearance of anti-HCV may occur in patients in whom HCV infections resolve. Conversely, anti-HCV persistence seems to be a sign ofchronicity. In our study, halfofthe sixpatients withacutely resolved hepatitis lostanti-HCV during follow-up; however, theantibody persisted in 80% of our patients who developed chronic hepatitis. In four patients, serum ALT levels continued to fluctuate after loss of anti-HCV ( figure 2, case21) . Although lossofanti-HCV may occur in patients in whom hepatitis resolves, it is not known if these patients remain infectious.
Since the presentHCV antibody assay cannot reliably distinguish between infectious and noninfectious blood in patients with HCV infections [13] , it probably indicates an immune response to nonstructural protein of HCY. Thepresent test, willassistclinicians and scientists in identifying and studying the epidemiology of HCV infections and will also assistsignificantly in screening out blooddonors who might transmit HCV.
